https://www.valotx.com/ 2023-05-22T09:47:56+01:00 1.0 https://www.valotx.com/article/valo-therapeutics-recruits-petri-priha-vice-president-cmc 2017-03-28T10:40:05+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-closes-seed-fundraising-round-develop-novel-oncolytic-virus-based-cancer 2017-01-30T11:06:18+00:00 0.5 https://www.valotx.com/article/bms-offers-850m-british-oncolytic-virus 2017-01-26T11:24:23+00:00 0.5 https://www.valotx.com/article/oncolytic-viruses-undervalued-technology-strong-growth-perspectives 2017-01-26T11:13:16+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-paatti-siemenrahoituskierroksen-kehittaakseen-uutta-onkolyyttiseen 2017-01-30T11:06:29+00:00 0.5 https://www.valotx.com/article/drug-discovery-and-development-immunotherapy-training-body-fight-cancer 2017-02-08T12:01:12+00:00 0.5 https://www.valotx.com/article/immuno-oncology-news-valo-therapeutics-developing-unique-viral-particle-cancer-vaccine 2017-02-08T12:10:20+00:00 0.5 https://www.valotx.com/article/adenoviruses-and-immune-system-join-forces-against-cancer 2017-09-14T14:26:28+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-receives-46-million-non-dilutive-funding-tekes-order-accelerate 2017-07-04T10:37:54+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-recruits-charlotta-backman-vp-clinical-operations-and-regulatory-affairs 2017-09-04T11:50:02+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-developing-virus-based-immunotherapy-defeat-cancer 2017-09-14T14:28:56+01:00 0.5 https://www.valotx.com/article/nature-cancer-killing-viruses-show-promise-and-draw-billion-dollar-investment 2018-05-09T10:24:08+01:00 0.5 https://www.valotx.com/article/oncolytics-dawn-new-era-cancer-treatment 2018-08-06T10:13:53+01:00 0.5 https://www.valotx.com/article/dnatrix-and-valo-therapeutics-enter-strategic-partnership-develop-peptide-coated-oncolytic 2018-11-13T17:12:37+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-appoints-michael-stein-chief-executive-officer 2019-06-17T07:10:59+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-acquires-peptienv-technology-university-helsinki 2019-09-02T11:55:40+01:00 0.5 https://www.valotx.com/article/biocentury-innovations-emerging-company-profile-valo-adding-tumor-antigens-oncolytic 2022-06-17T12:13:06+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-receives-prize-third-annual-lyfebulb-helsinn-cancer-innovation-summit 2020-02-03T09:05:06+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-new-funding-immuno-oncology-trials 2020-02-06T09:59:49+00:00 0.5 https://www.valotx.com/article/startup-making-cancer-vaccine-out-viruses 2020-04-03T09:35:16+01:00 0.5 https://www.valotx.com/article/targovax-and-valo-therapeutics-enter-collaboration-develop-ras-neoantigen-coating-oncos 2020-04-22T05:50:06+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-support-development-pan-coronavirus-vaccine 2020-04-27T06:58:39+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-board-appointment-dr-mai-britt-zocca 2022-06-28T07:50:59+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-appoints-industry-veteran-paul-g-higham-ceo 2020-08-03T07:57:57+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-granted-usa-patent-pepticrad-technology-cancer-immunotherapy 2020-11-24T09:51:38+00:00 0.5 https://www.valotx.com/article/scientific-publication-characterization-novel-ox40-ligand-and-cd40-ligand-expressing 2022-06-17T12:14:07+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-and-immunoscape-collaboration-identifies-immunogenic-peptides-develop-pan 2022-06-17T12:13:50+01:00 0.5 https://www.valotx.com/article/developing-vaccine-protects-against-covid-19-variants 2021-03-15T11:17:12+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-acquires-university-helsinkis-peptibac-cancer-and-infectious-disease 2021-04-19T08:35:25+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-clinical-trial-application-submission-german-phase-i-oncology 2022-06-17T12:14:35+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-eu11m-fundraise-advance-pepticrad-immunotherapy-platform-clinic 2022-06-17T12:16:09+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-acquires-university-helsinkis-technology-capitalizes-pre-existing 2022-01-06T08:11:58+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-appoints-hemanshu-shah-chief-business-officer 2022-06-16T14:59:22+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-appoints-experienced-life-sciences-executive-anthony-giovinazzo-board 2022-06-28T07:49:41+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-acquires-peptichip-technology-enabling-rapid-identification-tumor 2022-07-26T08:00:01+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-scientific-advisory-board 2022-08-02T09:06:50+01:00 0.5 https://www.valotx.com/article/read-about-what-were-doing-precision-oncology-news 2022-08-15T12:35:05+01:00 0.5 https://www.valotx.com/article/nordic-life-sciences-interview-valo-therapeutics-ceo-paul-higham 2022-09-19T14:01:48+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-selects-exothera-develop-large-scale-oncolytic-adenovirus-manufacturing 2023-01-11T11:05:59+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-secures-eur-223-million-european-innovation-council-progress-innovative 2023-02-14T07:01:08+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-two-european-patents-granted-its-lead-asset-pepticrad-1-immuno 2023-02-16T07:36:12+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-first-patient-dosed-pepticrad-1-innovative-immuno-oncology 2023-05-23T07:49:42+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-and-texcell-announce-research-collaboration-evaluate-immune-responses 2023-06-13T08:16:19+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-acquisition-bruker-corporations-latest-mass-spectrometer 2023-10-10T09:48:02+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-regulatory-approval-expand-phase-i-immuno-oncology-trial 2023-11-29T08:01:53+00:00 0.5 https://www.valotx.com/article/leadership-change 2024-04-22T08:01:33+01:00 0.5 https://www.valotx.com/article/lisata-therapeutics-and-valo-therapeutics-announce-preclinical-research-collaboration 2024-11-07T10:31:54+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-eur-19m-investment-funding-and-expanded-clinical-trials 2025-03-10T07:53:56+00:00 0.5 https://www.valotx.com/article/valotx-appoints-marcella-origgi-johnson-johnson-innovation-ceo 2025-04-09T08:03:01+01:00 0.5 https://www.valotx.com/article/valo-therapeutics-announces-positive-interim-results-pepticrad-1-phase-1-clinical-trial 2025-07-03T11:44:24+01:00 0.5 https://www.valotx.com/article/aifa-authorizes-clinical-trial-pepticrad-1-combination-pembrolizumab-italy 2026-01-26T10:27:16+00:00 0.5 https://www.valotx.com/article/valo-therapeutics-hosts-investigator-meeting-genoa-italy-phase-i-clinical-trial-pepticrad-1 2026-03-18T08:35:32+00:00 0.5 https://www.valotx.com/careers/valotx-not-currently-hiring 2023-09-22T20:52:00+01:00 0.5 https://www.valotx.com/contact-us 2021-02-03T10:05:44+00:00 0.5 https://www.valotx.com/node/1 2023-05-22T09:47:56+01:00 0.5 https://www.valotx.com/privacy-policy 2023-12-14T11:05:25+00:00 0.5 https://www.valotx.com/disclaimer 2017-01-16T16:21:00+00:00 0.5 https://www.valotx.com/about 2023-05-22T09:49:40+01:00 0.5 https://www.valotx.com/valotx-approach-and-technologies 2022-10-05T09:50:07+01:00 0.5 https://www.valotx.com/current-oncolytic-virus-approaches 2018-12-12T13:52:15+00:00 0.5 https://www.valotx.com/current-cancer-peptide-vaccines 2018-12-12T13:52:47+00:00 0.5 https://www.valotx.com/page-not-found 2017-01-13T14:43:26+00:00 0.5 https://www.valotx.com/access-denied 2017-01-13T14:44:34+00:00 0.5 https://www.valotx.com/terms-use 2017-01-17T10:43:22+00:00 0.5 https://www.valotx.com/careers-introduction 2017-01-20T08:45:43+00:00 0.5 https://www.valotx.com/svg-graphics 2019-12-16T11:15:43+00:00 0.5 https://www.valotx.com/peptichip 2023-06-01T12:02:22+01:00 0.5